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Background:  Both angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin-2 receptor blockers (ARBs) improve insulin resistance and 
vascular dysfunction in diabetic patients. Both ACE-Is and ARBs limit myocardial infarct size (IS) in non-diabetic animal models. However, a recent 
study suggested that valsartan (VA) up to 10 mg/kg/d does not limit IS in diabetic rats. The effects of aliskiren (AL), a direct rennin inhibitor on 
ischemia-reperfusion injury is unknown. We assessed the effects of oral aliskiren (AL), VA, alone and in combination; on myocardial IS in diabetic 
mice. 
Methods:  Db/Db mice, fed Western Diet, received 15-day pretreatment with: 1) vehicle; 2) AL 25mg/kg/d; 3) AL 50mg/kg/d; 4) VA 8mg/kg/d; 5) 
VA 16mg/kg/d; 6) AL 25+VA 16mg/kg/d; or 7) AL 50+VA 16mg/kg/d. Mice underwent 30min coronary artery occlusion and 4h reperfusion. Area at 
risk (AR) was assessed by blue dye and IS by TTC staining (blinded to treatment group). 
Results:  Body weight, left ventricular weight and the size of the AR were comparable among groups. AL at 25 and 50 mg/kg/d reduced IS. VA at 16 
mg/kg/d, but not at 8 mg/kg/d, limited IS. The combination of AL+VA had additive effects, as IS was the smallest in the AL50+VA16 group (Figure. * 
p<0.001 vs. control; # p<0.008 vs. A50+VA16). 
Conclusions:  AL, a direct rennin inhibitor, and high-dose VA limit myocardial IS. The combination of AL and VA may have additive effects in 
protecting the diabetic heart against ischemia-reperfusion injury. 
